Natixis Bluebird Bio, Inc. Transaction History

Natixis

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$16.59 - $33.89 $2.09 Million - $4.28 Million	-126,169 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$27.5 - $37.92 $3.47 Million - $4.78 Million	126,169 New	126,169 $5.46 Million
Q3 2020 Nov 12, 2020	SELL	$34.44 - $43.75 $1.8 Million - $2.29 Million	-52,400 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$27.12 - $45.97 $1.42 Million - $2.41 Million	52,400 New	52,400 $3.2 Million

27M

191K

299K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $561M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.